Beeline Medicines launched with five programs licensed from Bristol Myers Squibb and secured a $300 million Series A led by Bain Capital. The company’s portfolio is built around therapies for immune-mediated conditions, beginning with afimetoran, a once-daily oral selective TLR7/8 inhibitor for lupus. Afimetoran received fast track designation for systemic lupus erythematosus (SLE) in May 2025 and has cutaneous lupus erythematosus proof-of-concept data. Beeline expects its Phase II trial to conclude in the second half of 2026. The in-portfolio pipeline also includes BMS-986326 (an IL-2/CD25 fusion protein for Treg modulation) and lomedeucitinib (a TYK2 inhibitor for rare immune diseases), plus biologics aimed at IL-18 and IL-10. The creation of Beeline signals continued investor appetite for focused stand-alone platforms built around validated modality biology, and it emphasizes a development plan that could accelerate lupus and broader autoimmune expansion from pre-defined BMS assets.